These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 25511521)
1. Anterior cingulate dopamine turnover and behavior change in Parkinson's disease. Gallagher CL; Bell B; Palotti M; Oh J; Christian BT; Okonkwo O; Sojkova J; Buyan-Dent L; Nickles RJ; Harding SJ; Stone CK; Johnson SC; Holden JE Brain Imaging Behav; 2015 Dec; 9(4):821-7. PubMed ID: 25511521 [TBL] [Abstract][Full Text] [Related]
2. A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease. Li CT; Palotti M; Holden JE; Oh J; Okonkwo O; Christian BT; Bendlin BB; Buyan-Dent L; Harding SJ; Stone CK; DeJesus OT; Nickles RJ; Gallagher CL Synapse; 2014 Aug; 68(8):325-31. PubMed ID: 24710997 [TBL] [Abstract][Full Text] [Related]
3. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426 [TBL] [Abstract][Full Text] [Related]
4. The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. Wu K; O'Keeffe D; Politis M; O'Keeffe GC; Robbins TW; Bose SK; Brooks DJ; Piccini P; Barker RA Brain; 2012 Aug; 135(Pt 8):2449-57. PubMed ID: 22843413 [TBL] [Abstract][Full Text] [Related]
5. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA. Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism. Ishiwata K; Shinoda M; Ishii S; Nozaki T; Senda M Nucl Med Biol; 1996 Apr; 23(3):295-301. PubMed ID: 8782240 [TBL] [Abstract][Full Text] [Related]
7. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Tohgi H; Abe T; Yamazaki K; Saheki M; Takahashi S; Tsukamoto Y Neurosci Lett; 1995 Jun; 192(3):165-8. PubMed ID: 7566641 [TBL] [Abstract][Full Text] [Related]
9. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). Jorga KM; Nicholl DJ Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160 [TBL] [Abstract][Full Text] [Related]
10. Cognitive improvement during Tolcapone treatment in Parkinson's disease. Gasparini M; Fabrizio E; Bonifati V; Meco G J Neural Transm (Vienna); 1997; 104(8-9):887-94. PubMed ID: 9451720 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
12. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies. Nagano-Saito A; Kato T; Arahata Y; Washimi Y; Nakamura A; Abe Y; Yamada T; Iwai K; Hatano K; Kawasumi Y; Kachi T; Dagher A; Ito K Neuroimage; 2004 Jun; 22(2):553-61. PubMed ID: 15193583 [TBL] [Abstract][Full Text] [Related]
13. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats. Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869 [TBL] [Abstract][Full Text] [Related]
14. Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with ¹⁸F-dopa brain PET in normal controls and patients with Parkinson's disease. Oehme L; Perick M; Beuthien-Baumann B; Wolz M; Storch A; Löhle M; Herting B; Langner J; van den Hoff J; Reichmann H; Kotzerke J Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1550-9. PubMed ID: 21553090 [TBL] [Abstract][Full Text] [Related]
15. Sexually dimorphic effects of catechol-O-methyltransferase (COMT) inhibition on dopamine metabolism in multiple brain regions. Laatikainen LM; Sharp T; Harrison PJ; Tunbridge EM PLoS One; 2013; 8(4):e61839. PubMed ID: 23613951 [TBL] [Abstract][Full Text] [Related]
16. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys. Doudet DJ; Chan GL; Holden JE; Morrison KS; Wyatt RJ; Ruth TJ Neuropharmacology; 1997 Mar; 36(3):363-71. PubMed ID: 9175615 [TBL] [Abstract][Full Text] [Related]
17. Effects of tolcapone on working memory and brain activity in abstinent smokers: a proof-of-concept study. Ashare RL; Wileyto EP; Ruparel K; Goelz PM; Hopson RD; Valdez JN; Gur RC; Loughead J; Lerman C Drug Alcohol Depend; 2013 Dec; 133(3):852-6. PubMed ID: 24095246 [TBL] [Abstract][Full Text] [Related]
18. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Brück A; Aalto S; Nurmi E; Bergman J; Rinne JO Neurobiol Aging; 2005 Jun; 26(6):891-8. PubMed ID: 15718048 [TBL] [Abstract][Full Text] [Related]
19. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296 [TBL] [Abstract][Full Text] [Related]
20. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice. Detrait ER; Carr GV; Weinberger DR; Lamberty Y Behav Pharmacol; 2016 Aug; 27(5):415-21. PubMed ID: 26919286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]